Molbio Diagnostics IPO
GMP, Subscription, Price, Dates & Financial Details
Medical Equipment/supplies/accessories
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of innovative rapid diagnostic solutions for infectious and non-communicable diseases.The company has…
Open Date
Mon, 10 Aug 2026
Close Date
Wed, 12 Aug 2026
Price Band
₹ 768 – 807
Lot Size
18
Issue Size
₹ 939.70 Cr
Minimum Investment
₹ 14,526 (18 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
According to the Red Herring Prospectus (RHP), Molbio Diagnostics IPO was a book-built issue with a total issue size of ₹940 Crore, comprising a fresh issue of 24.80 Lakh equity shares aggregating to ₹200.00 Crore and an offer for sale (OFS) of 91.66 Lakh equity shares aggregating to ₹739.70 Crore by the existing shareholders.
The Molbio Diagnostics IPO was open for subscription from August 10, 2026, to August 12, 2026. The basis of allotment was finalized on August 13, 2026, and the shares are tentatively scheduled to be listed on the NSE and BSE on August 17, 2026.
The company had fixed the price band at ₹768 to ₹807 per share, with a lot size of 18 shares. Retail investors were required to make a minimum investment of ₹14,526 (based on the upper price band) to apply for one lot.
The IPO also included a reservation of 20,520 equity shares for eligible employees, who were offered a discount of ₹76.00 per share.
KFin Technologies Limited is the registrar to the issue. IIFL Capital Services Limited, Motilal Oswal Investment Advisors Ltd, Jefferies India Private Limited, and Kotak Mahindra Capital Company Limited are the Book Running Lead Managers (BRLMs) to the issue.
Following the completion of the allotment process, successful applicants should receive the allotted shares in their demat accounts before the tentative listing on the NSE and BSE on August 17, 2026. Investors who did not receive an allotment can expect their refunds, if applicable, to be processed as per the IPO schedule.
Molbio Diagnostics IPO Timeline (Tentative)
- IPO Open Date
- Mon, 10 Aug 26
- IPO Close Date
- Wed, 12 Aug 26
- Basis of Allotment
- Thu, 13 Aug 26
- Initiation of Refunds
- Fri, 14 Aug 26
- Credit of Shares to Demat
- Fri, 14 Aug 26
- Listing Date
- Mon, 17 Aug 26 — NSE & BSE
Open Date
10 August 2026
Close Date
12 August 2026
Basis Of Allotment
13 August 2026
Listing Date
17 August 2026
IPO Subscription
Check Live Subscription →The Molbio Diagnostics IPO has received bids for 57,32,14,536 shares against 81,58,529 shares offered, resulting in an overall subscription of 70.26x. the NII category is subscribed 49.8x, Retail Investors 12.96x, Employees 13.28x, and QIBs 186.39x. Within the NII category, BNII is subscribed 50.82x, while SNII is subscribed 47.76x.
QIB
186.39x
NII
49.8x
BNII
50.82x
SNII
47.76x
RII
12.96x
EMP
13.28x
Total
70.26x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 40,69,004 shares, representing 34.94% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 23,25,146 shares (19.96%), while Non-Institutional Investors (NIIs) receive 17,43,859 shares (14.97%).
| Category | Shares Offered | Shares Offered |
|---|---|---|
| Anchor Investors | 3,487,717 | 29.95% |
| Qualified Institutions | 2,325,146 | 19.96% |
| Non-Institutional | 1,743,859 | 14.97% |
| BNII | 1,162,573 | 9.98% |
| SNII | 581,286 | 4.99% |
| Retail Investors | 4,069,004 | 34.94% |
| Employees | 20,520 | 0.18% |
| Total | 11,646,246 | 100% |
Financials Details(₹ in Crores)
| Particular | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 2148.42 | 1461.56 | 1221.06 |
| Revenue | 1455.17 | 1027.94 | 840.66 |
| Profit After Tax | 164.14 | 138.58 | 83.54 |
| Net Worth | 1144.68 | 952.95 | 807.94 |
| Reserve & Surplus | 1148.84 | 990.84 | 845.48 |
| Total Borrowings | 412.64 | 123.16 | 174.58 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Molbio Diagnostics Limited KPI Information
| Particular | Mar 2026 | Mar 2025 | Mar 2024 |
|---|---|---|---|
| ROE % | 15.59 | 16.2 | 13.2 |
| ROCE % | 17.55 | 20.98 | 15.8 |
| RoNW % | 14.55 | 15.23 | 12.62 |
| Pat Margin % | 11.28 | 13.48 | 9.94 |
Peers Comparison
| Company | Face Value | PE Ratio | EPS Basic | EPS Diluted | RoNW | Net Assets |
|---|---|---|---|---|---|---|
| Molbio Diagnostics Ltd | 1 | 0 | 14.77 | 14.77 | 14.55 | 101.51 |
| Poly Medicure Ltd | 5 | 52.61 | 31.79 | 31.75 | 10.37 | 306.45 |
| Dr. Lal Pathlabs Ltd | 10 | 62.2 | 30.24 | 30.2 | 20.78 | 145 |
| Metropolis Healthcare Ltd | 2 | 63.72 | 9.19 | 9.19 | 12.56 | 72.98 |
| Vijaya Diagnostic Centre Ltd | 1 | 81.02 | 16.81 | 16.79 | 18.07 | 93.02 |
About Molbio Diagnostics Limited
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of innovative rapid diagnostic solutions for infectious and non-communicable diseases.
The company has developed its proprietary Truenat platform, a portable, battery-operated, PCR-based molecular diagnostics system specifically designed for resource-limited settings. The platform delivers highly accurate molecular test results within approximately one hour, enabling timely diagnosis and treatment at the point of care.
Molbio offers a comprehensive portfolio of molecular diagnostic solutions covering more than 30 diseases through 43 diagnostic assays. Its product portfolio includes tests for tuberculosis (TB), COVID-19, HIV, Hepatitis B, Hepatitis C, Human Papillomavirus (HPV), and several other infectious diseases. In addition to molecular diagnostics, the company provides advanced healthcare solutions in radiology, digital pathology, and breast health screening through its subsidiaries and strategic partnerships. Molbio continues to strengthen its product pipeline through significant investments in in-house research and development.
The company operates six state-of-the-art manufacturing facilities across India and serves customers in more than 90 countries. Its diverse customer base includes government healthcare programs, public and private hospitals, diagnostic laboratories, research institutions, and international healthcare organizations. Supported by a robust intellectual property portfolio, global quality certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in the molecular diagnostics industry.
As of March 31, 2026, Molbio Diagnostics Limited employed 1,225 permanent employees across various functions, including research and development, manufacturing, quality assurance, regulatory affairs, sales and marketing, finance, information technology, and corporate operations.
Molbio Diagnostics IPO Promoters
- Chandrasekhar Bhaskaran Nair
- Exxora Trading LLP
- Sangeetha Sriram
- Shiva Sriram
- Sowmya Sriram
- Sriram Natarajan
Promoters Holding
Holding Pre Issue
46.65%
Holding Post Issue
43.01%
Molbio Diagnostics IPO Objective
The Company Molbio Diagnostics IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Funding capital expenditure towards the setting up of infrastructure for our research and development facility, Center of Excellence and connected office space
- Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit
- General corporate purposes
Molbio Diagnostics Limited Address / Contact Details
Molbio Diagnostics Limited
Plot No. L-46
Phase II-D, Verna Industrial Area
Verna, Salcete South Goa, Goa, 403722
Telephone: +91 832 672488
Email: investors@molbiodiagnostics.com
Website: https://www.molbiodiagnostics.com/
IPO Snapshot
Molbio Diagnostics IPO Lot Size
The Molbio Diagnostics IPO has a lot size of 18 shares. Retail investors require a minimum investment of ₹14,526 by applying for 1 lot (18 shares). The maximum application allowed for the retail category is 13 lots (234 shares), requiring an investment of ₹1,88,838.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 18 | 14,526.00 |
| Retail (Max) | 13 | 234 | 188,838.00 |
| S-HNI (Min) | 14 | 252 | 203,364.00 |
| S-HNI (Max) | 68 | 1,224 | 987,768.00 |
| B-HNI (Min) | 69 | 1,242 | 1,002,294.00 |
Issue Reservation
- Anchor Investors — 29.95%
- QIB — 19.96%
- NII — 14.97%
- RII — 34.94%
- EMP — 0.18%
Book Running Lead Managers
- IIFL Capital Services Limited
- Motilal Oswal Investment Advisors Ltd
- Jefferies India Private Limited
- Kotak Mahindra Capital Company Limited
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Molbio Diagnostics IPO?
Molbio Diagnostics IPO is a Book-building IPO with a total issue size of ₹939.7 crore. The Molbio Diagnostics IPO price band is ₹768 to 807 per share. The Molbio Diagnostics IPO subscription opens on Mon, Aug 10, 2026, and closes on Wed, Aug 12, 2026. The Molbio Diagnostics IPO will be listed on the BSE,NSE. KFin Technologies Limited is the registrar for the Molbio Diagnostics IPO.
When will the Molbio Diagnostics IPO open for subscription?
The Molbio Diagnostics IPO opens on Mon, Aug 10, 2026 and closes on Wed, Aug 12, 2026
What is Molbio Diagnostics IPO Price Band?
Molbio Diagnostics IPO Price Band is ₹768 to 807 per share.
What is Molbio Diagnostics IPO Lot Size?
Molbio Diagnostics IPO lot size is 18 shares, Retail investors need a minimum investment of ₹14526 based on the upper price band
What is the minimum investment for Molbio Diagnostics IPO?
The minimum investment for Molbio Diagnostics IPO is ₹14526, based on one lot of 18 shares at the upper price band of ₹807 per share.
How to apply for Molbio Diagnostics IPO?
Investors can apply for the Molbio Diagnostics IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Wed, Aug 12, 2026. The application amount remains blocked until the Molbio Diagnostics IPO allotment is finalized.
What is Molbio Diagnostics IPO Issue Size?
Molbio Diagnostics IPO issue size is ₹939.7 crores.
What is the Molbio Diagnostics IPO Allotment Date?
Molbio Diagnostics IPO allotment date is Thu, Aug 13, 2026.
Who is the Molbio Diagnostics IPO Registrar?
The registrar for Molbio Diagnostics IPO is KFin Technologies Limited. Investors can go to KFin Technologies Limited website to check Molbio Diagnostics IPO allotment status, refund processing, and other IPO-related information.
What is the Molbio Diagnostics IPO GMP?
The Molbio Diagnostics IPO GMP (Grey Market Premium) is ₹220 as of Thu, Aug 6, 2026. Based on the upper price band of ₹807 per share, the estimated Molbio Diagnostics IPO listing price is ₹1027, indicating a potential listing gain of approximately 27.26% over the issue price.
Who is the Molbio Diagnostics IPO Lead Manager?
The book-running lead managers (BRLMs) for the Molbio Diagnostics IPO are Motilal Oswal Investment Advisors Ltd, Jefferies India Private Limited, and Kotak Mahindra Capital Company Limited. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Molbio Diagnostics IPO Red Herring Prospectus (RHP).